Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 3/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 4/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041266 | 0.95 | RIPK2 (0.42) | RIPK2ACVR1NOD2TNK2CAMK2D | |
| SCHEMBL14682001 | 0.89 | RIPK2 (0.47) | RIPK2ACVR1NOD2TNK2CAMK2D | |
| SCHEMBL15787914 | 0.84 | RIPK2 (0.43) | RIPK2ACVR1NOD2TNK2CAMK2D | |
| SCHEMBL15281053 | 0.81 | RIPK2 (0.46) | RIPK2ACVR1NOD2TNK2SRC | |
| SCHEMBL15041477 | 0.74 | PAK4 (0.45) | RIPK2ACVR1NOD2PAK4PKN1 | |
| SCHEMBL13553932 | 0.74 | PAK4 (0.54) | TNK2PAK4PKN1SRC | |
| SCHEMBL14682004 | 0.73 | RIPK2 (0.46) | RIPK2ACVR1NOD2TNK2PAK4 | |
| SCHEMBL15035795 | 0.73 | PKN1 (0.55) | RIPK2ACVR1NOD2TNK2PAK4 | |
| SCHEMBL14681979 | 0.72 | CAMK2D (0.56) | RIPK2ACVR1NOD2TNK2CAMK2D | |
| SCHEMBL15036122 | 0.71 | RIPK2 (0.47) | RIPK2ACVR1NOD2TNK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | RIPK2 971/4885ACVR1 4752/4885NOD2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.